Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.71 |
| ▸ | MAOA | P21397 | 6/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | CDK4 | P11802 | 1/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.63 |
| ▸ | CCND1 | P24385 | 1/20 | 0.63 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TLR4 | O00206 | 1/20 | 0.58 |
| ▸ | TLR2 | O60603 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799252 | 0.90 | LCK (0.58) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL19871639 | 0.86 | MAOB (0.54) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL5987640 | 0.86 | MAOB (0.56) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL11903271 | 0.85 | MAOB (0.61) | MAOBMAOALCKTLR4TLR2 | |
| SCHEMBL7901722 | 0.85 | MAOB (0.53) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL314161 | 0.83 | MAOB (1.00) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL29454637 | 0.83 | MAOB (1.00) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL27786357 | 0.83 | MAOB (0.71) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL5545087 | 0.83 | MAOB (0.71) | MAOBMAOALCKCCNB2CDK1 | |
| SCHEMBL17821810 | 0.81 | LCK (0.74) | MAOBMAOALCKCCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362814-B | Synthetic method of rivastigmine chiral intermediate | 暨明医药科技（苏州）有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-111362814-A | Synthetic method of rivastigmine chiral intermediate | 暨明医药科技（苏州）有限公司 | 2020-07-03 | — | — | CN | claimed |
| CN-102050705-B | Novel method for preparing resveratrol through decarbonylation heck reaction | CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD | 2013-07-31 | — | — | CN | claimed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-111362814-B | Synthetic method of rivastigmine chiral intermediate | 暨明医药科技（苏州）有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-111362814-B | Synthetic method of rivastigmine chiral intermediate | 暨明医药科技（苏州）有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-111362814-A | Synthetic method of rivastigmine chiral intermediate | 暨明医药科技（苏州）有限公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-111362814-A | Synthetic method of rivastigmine chiral intermediate | 暨明医药科技（苏州）有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-2721446-B1 | ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC-RAY- OR RADIATION-SENSITIVE FILM THEREFROM AND METHOD OF FORMING PATTERN | FUJIFILM CORP (JP) | 2017-11-22 | — | — | EP | disclosed |
| CN-101039947-A | Inhibitors of hcv replication | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | CN | disclosed |
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1724278-A1 | NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6057357-A | USEFUL IN TREATING PAIN, INFLAMMATION, PSORIASIS AND IRRITABLE BOWEL SYNDROME | WARNER-LAMBERT COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1998049158-A1 | PERIPHERALLY SELECTIVE KAPPA OPIOID AGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| CN-1037141-A | The alkylamine derivative that replaces | BANYU PHARMA CO LTD (JP) | 1989-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191289-A1 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs | SLC5A1, SLC5A2, GPR119 | MAOB 1207/4885MAOA 1784/4885LCK 3408/4885 |
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | MAOB 290/4885MAOA 348/4885LCK 3538/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | MAOB 4333/4885MAOA 4009/4885LCK 3586/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | MAOB 2142/4885MAOA 2062/4885LCK 1044/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | MAOB 290/4885MAOA 348/4885LCK 3538/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | MAOB 290/4885MAOA 348/4885LCK 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.